Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
176.5 NOK | -2.49% | +0.86% | -17.52% |
Apr. 25 | Transcript : Medistim ASA, Q1 2024 Earnings Call, Apr 25, 2024 | |
Apr. 24 | Medistim ASA Approves Dividend for the Year 2023, Payable on May 6, 2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 30.07 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-17.52% | 298M | - | ||
+7.84% | 218B | B | ||
+7.35% | 184B | B- | ||
+13.04% | 135B | B- | ||
+26.03% | 107B | A- | ||
-1.33% | 62.38B | A- | ||
+11.80% | 51.37B | B+ | ||
+4.81% | 50.9B | B+ | ||
+0.30% | 40.87B | A | ||
+2.78% | 36.28B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- MEDI Stock
- Ratings Medistim ASA